Brought to you by 
BI and Vitae partner on 11beta-HSD1 inhibitors for diabetes
29 Jun 2015
Executive Summary
Boehringer Ingelheim GMBH and small-molecule drug developer Vitae Pharmaceuticals have agreed to identify 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors for diabetes and other metabolic diseases such as obesity and dyslipidemia, and for hypertension. The companies will combine their respective programs and identify candidates to advance toward clinical testing.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BI and Vitae partner on 11beta-HSD1 inhibitors for diabetes
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice